ERBB2 and breast cancer: This hypothesis is supported by the results of the interim analysis of the WSG-ADAPT phase II trial, which demonstrated pCR rates of more than 40% after short dual-HER2 blockade using trastuzumab emtansine combined with endocrine therapy, without systemic chemotherapy, in HR+/HER2+ early-stage breast cancer [36].